Holdings
Stonepine Capital Management, LLC
As of Sep 30, 2026, Stonepine Capital Management, LLC reported 61 positions worth US$116M. Largest: Verastem, Inc., CAMP4 Therapeutics Corporation and Evolus, Inc. Common Stock. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Verastem, Inc. | 3.04M | US$24.5M | −307K | Sep 30, 2026 |
| CAMP4 Therapeutics Corporation | 2.79M | US$11.3M | +1.4M | Sep 30, 2026 |
| Evolus, Inc. Common Stock | 972K | US$7.77M | −619K | Sep 30, 2026 |
| ADMA Biologics Inc | 700K | US$7.02M | −40,000 | Sep 30, 2026 |
| Nektar Therapeutics | 110K | US$6.66M | −10,654 | Sep 30, 2026 |
| Eloxx Pharmaceuticals, Inc. | 382K | US$5.85M | −15,183 | Sep 30, 2026 |
| Satellos Bioscience Inc | 455K | US$3.87M | −36,566 | Sep 30, 2026 |
| Kazia Therapeutics Ltd | 377K | US$3.62M | new | Sep 30, 2026 |
| Indivior Pharmaceuticals, Inc. | 100K | US$3.58M | no change | Sep 30, 2026 |
| Ultragenyx Pharmaceutical Inc. | 210K | US$3.16M | +185K | Sep 30, 2026 |